Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (116)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Anderson, J.
Right arrow Articles by Heath, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, J.
Right arrow Articles by Heath, J. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 7, 1475-1483, Copyright © 1998 by Oxford University Press

ARTICLES

Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand

J Anderson, HD Burns, P Enriquez-Harris, AOM Wilkie and JK Heath
School of Biochemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Dominantly acting mutations of the fibroblast growth factor (FGF) receptor 2 (FGFR2) gene have been implicated in various craniosynostosis syndromes. Apert syndrome, characterized in addition by syndactyly of the limbs, involves specific mutations at two adjacent residues, Ser252Trp and Pro253Arg, predicted to lie in the linker region between IgII and IgIII of the FGFR2 ligand-binding domain. We have analysed the interaction of FGF ligands with wild-type and Apert- type mutant FGFR2 ectodomains in solution. Wild-type and Apert-type receptors form a complex with FGF ligands with a stoichiometry of 2:2 (ligand:receptor). The kinetics and specificity of ligand binding to wild-type and Apert mutant receptors have been analysed using surface plasmon resonance techniques. This reveals that Apert mutations, compared with wild-type, exhibit a selective decrease in the dissociation kinetics of FGF2, but not of other FGF ligands examined. In contrast, the substitution Ser252Leu in FGFR2, previously observed in several asymptomatic individuals, exhibited wild-type kinetics. These findings indicate that Apert syndrome arises as a result of increased affinity of mutant receptors for specific FGF ligands which leads to activation of signalling under conditions where availability of ligand is limiting.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
U. M. Polanska, L. Duchesne, J. C. Harries, D. G. Fernig, and T. K. Kinnunen
N-Glycosylation Regulates Fibroblast Growth Factor Receptor/EGL-15 Activity in Caenorhabditis elegans in Vivo
J. Biol. Chem., November 27, 2009; 284(48): 33030 - 33039.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Ota, Z.-Q. Zhou, J. M. Link, and P. J. Hurlin
The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects
Hum. Mol. Genet., July 15, 2009; 18(14): 2609 - 2621.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Miraoui, K. Oudina, H. Petite, Y. Tanimoto, K. Moriyama, and P. J. Marie
Fibroblast Growth Factor Receptor 2 Promotes Osteogenic Differentiation in Mesenchymal Cells via ERK1/2 and Protein Kinase C Signaling
J. Biol. Chem., February 20, 2009; 284(8): 4897 - 4904.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Dutt, H. B. Salvesen, T.-H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nicoletti, W. Winckler, R. Grewal, M. Hanna, et al.
Drug-sensitive FGFR2 mutations in endometrial carcinoma
PNAS, June 24, 2008; 105(25): 8713 - 8717.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. E. Hatch, M. Hudson, M. L. Seto, M. L. Cunningham, and M. Bothwell
Intracellular Retention, Degradation, and Signaling of Glycosylation-deficient FGFR2 and Craniosynostosis Syndrome-associated FGFR2C278F
J. Biol. Chem., September 15, 2006; 281(37): 27292 - 27305.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
Y. Wang, R. Xiao, F. Yang, B. O. Karim, A. J. Iacovelli, J. Cai, C. P. Lerner, J. T. Richtsmeier, J. M. Leszl, C. A. Hill, et al.
Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse
Development, August 1, 2005; 132(15): 3537 - 3548.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Goriely, G. A. T. McVean, A. M. M. van Pelt, A. W. O'Rourke, S. A. Wall, D. G. de Rooij, and A. O. M. Wilkie
Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia
PNAS, April 26, 2005; 102(17): 6051 - 6056.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
O. A. Ibrahimi, B. K. Yeh, A. V. Eliseenkova, F. Zhang, S. K. Olsen, M. Igarashi, S. A. Aaronson, R. J. Linhardt, and M. Mohammadi
Analysis of Mutations in Fibroblast Growth Factor (FGF) and a Pathogenic Mutation in FGF Receptor (FGFR) Provides Direct Evidence for the Symmetric Two-End Model for FGFR Dimerization
Mol. Cell. Biol., January 15, 2005; 25(2): 671 - 684.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
X. Li, V. G. Brunton, H. R. Burgar, L. M. Wheldon, and J. K. Heath
FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity
J. Cell Sci., December 1, 2004; 117(25): 6007 - 6017.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. Gonzalez-Martinez, S.-H. Kim, Y. Hu, S. Guimond, J. Schofield, P. Winyard, G. B. Vannelli, J. Turnbull, and P.-M. Bouloux
Anosmin-1 Modulates Fibroblast Growth Factor Receptor 1 Signaling in Human Gonadotropin-Releasing Hormone Olfactory Neuroblasts through a Heparan Sulfate-Dependent Mechanism
J. Neurosci., November 17, 2004; 24(46): 10384 - 10392.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Tanimoto, M. Yokozeki, K. Hiura, K. Matsumoto, H. Nakanishi, T. Matsumoto, P. J. Marie, and K. Moriyama
A Soluble Form of Fibroblast Growth Factor Receptor 2 (FGFR2) with S252W Mutation Acts as an Efficient Inhibitor for the Enhanced Osteoblastic Differentiation Caused by FGFR2 Activation in Apert Syndrome
J. Biol. Chem., October 29, 2004; 279(44): 45926 - 45934.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
O. A. Ibrahimi, F. Zhang, A. V. Eliseenkova, N. Itoh, R. J. Linhardt, and M. Mohammadi
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities
Hum. Mol. Genet., October 1, 2004; 13(19): 2313 - 2324.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. P. Eswarakumar, M. C. Horowitz, R. Locklin, G. M. Morriss-Kay, and P. Lonai
A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis
PNAS, August 24, 2004; 101(34): 12555 - 12560.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
M. K. Hajihosseini, M. D. Lalioti, S. Arthaud, H. R. Burgar, J. M. Brown, S. R. F. Twigg, A. O. M. Wilkie, and J. K. Heath
Skeletal development is regulated by fibroblast growth factor receptor 1 signalling dynamics
Development, January 15, 2004; 131(2): 325 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
O. A. Ibrahimi, F. Zhang, A. V. Eliseenkova, R. J. Linhardt, and M. Mohammadi
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity
Hum. Mol. Genet., January 1, 2004; 13(1): 69 - 78.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
A. Goriely, G. A. T. McVean, M. Rojmyr, B. Ingemarsson, and A. O. M. Wilkie
Evidence for Selective Advantage of Pathogenic FGFR2 Mutations in the Male Germ Line
Science, August 1, 2003; 301(5633): 643 - 646.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
K. Yu, J. Xu, Z. Liu, D. Sosic, J. Shao, E. N. Olson, D. A. Towler, and D. M. Ornitz
Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth
Development, July 1, 2003; 130(13): 3063 - 3074.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
V. P. Eswarakumar, E. Monsonego-Ornan, M. Pines, I. Antonopoulou, G. M. Morriss-Kay, and P. Lonai
The IIIc alternative of Fgfr2 is a positive regulator of bone formation
Development, March 10, 2003; 129(16): 3783 - 3793.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. K. Yeh, M. Igarashi, A. V. Eliseenkova, A. N. Plotnikov, I. Sher, D. Ron, S. A. Aaronson, and M. Mohammadi
Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors
PNAS, March 4, 2003; 100(5): 2266 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. K. Powell, D. G. Fernig, and J. E. Turnbull
Fibroblast Growth Factor Receptors 1 and 2 Interact Differently with Heparin/Heparan Sulfate. IMPLICATIONS FOR DYNAMIC ASSEMBLY OF A TERNARY SIGNALING COMPLEX
J. Biol. Chem., August 2, 2002; 277(32): 28554 - 28563.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
D. M. Ornitz and P. J. Marie
FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease
Genes & Dev., June 15, 2002; 16(12): 1446 - 1465.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. E. Kearns, M. M. Donohue, B. Sanyal, and M. B. Demay
Cloning and Characterization of a Novel Protein Kinase That Impairs Osteoblast Differentiation in Vitro
J. Biol. Chem., November 2, 2001; 276(45): 42213 - 42218.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
Q. Wang, R. P. Green, G. Zhao, and D. M. Ornitz
Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains
Development, October 1, 2001; 128(19): 3867 - 3876.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. A. Ibrahimi, A. V. Eliseenkova, A. N. Plotnikov, K. Yu, D. M. Ornitz, and M. Mohammadi
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome
PNAS, May 30, 2001; (2001) 121183798.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. K. Hajihosseini, S. Wilson, L. De Moerlooze, and C. Dickson
A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes
PNAS, March 27, 2001; 98(7): 3855 - 3860.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. A. Greenwald, B. J. Mehrara, J. A. Spector, S. M. Warren, P. J. Fagenholz, L. P. Smith, P. J. Bouletreau, F. E. Crisera, H. Ueno, and M. T. Longaker
In Vivo Modulation of FGF Biological Activity Alters Cranial Suture Fate
Am. J. Pathol., February 1, 2001; 158(2): 441 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Yu, A. B. Herr, G. Waksman, and D. M. Ornitz
Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome
PNAS, December 19, 2000; 97(26): 14536 - 14541.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
A. Mansukhani, P. Bellosta, M. Sahni, and C. Basilico
Signaling by Fibroblast Growth Factors (Fgf) and Fibroblast Growth Factor Receptor 2 (Fgfr2)-Activating Mutations Blocks Mineralization and Induces Apoptosis in Osteoblasts
J. Cell Biol., June 12, 2000; 149(6): 1297 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Chellaiah, W. Yuan, M. Chellaiah, and D. M. Ornitz
Mapping Ligand Binding Domains in Chimeric Fibroblast Growth Factor Receptor Molecules. MULTIPLE REGIONS DETERMINE LIGAND BINDING SPECIFICITY
J. Biol. Chem., December 3, 1999; 274(49): 34785 - 34794.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
O. A. Ibrahimi, A. V. Eliseenkova, A. N. Plotnikov, K. Yu, D. M. Ornitz, and M. Mohammadi
Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome
PNAS, June 19, 2001; 98(13): 7182 - 7187.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.